Les cellules géantes formées en présence de l’interleukine-17A dans les granulomes de tuberculose : mécanismes de formation, de survie et fonctions

Tuberculosis, caused by Mycobacterium tuberculosis infection, results in the development of granulomas in affected tissues. These structures are formed by a myeloid cell core including multinucleated giant cells and surrounded by T lymphocytes. We studied mechanisms of survival, formation and functions of giant cells in Mycobacterium granulomas. Previously, our group showed that the cytokine IL-17A induces the fusion of dendritic cells (DC). Here, we identified molecules induced by the IL-17A genetic program in myeloid cells: BFL1 regulated DC survival, while the chemokines CCL2 and CCL20 directed clustering required for DC fusion. In situ, in human TB granulomas, we found that IL-17A was expressed by T lymphocytes while BFL1, CCL2 and CCL20 were expressed by the mono- and multi-nucleated myeloid cells. Then we characterized phenotype, immune functions and microbicidal activity of IL-17A-treated DC and their derived giant cells. They expressed a mixed DC-macrophage phenotype, retained classical DC functions, synthesized several destructive enzymes and had increased and differential microbicidal activities against Mycobacterium species. We named GMIC (giant myeloid inflammatory cells) these IL-17A-dependent giant cells, and propose that they constitute a new inflammatory myeloid effector with potent microbicidal activities. Altogether, our results show that IL-17A may participate in the maintenance of the myeloid core of human tuberculosis granuloma by promoting the formation of GMIC with potent destructive and microbicidal functions. The molecular mechanisms we have documented should help the development of new tuberculosis therapeutic and vaccination strategies.Dans la tuberculose, Mycobacterium tuberculosis forme des granulomes dans les poumons avec, au centre, des cellules myéloïdes mono et multi-nucléées et autour, des lymphocytes. Nous avons étudié la biologie des cellules géantes dans ces granulomes tuberculeux : formation, mécanismes de survie et fonctions. Notre groupe a publié que l’IL-17A déclenche la fusion des cellules dendritiques (DC). Notre travail démontre que cette cytokine induit BCL2A1/BFL1, qui régule la survie des DC et les chémokines CCL2 et CCL20 qui dirigent le regroupement nécessaire à leur fusion. In situ, l'IL-17A est exprimée par les lymphocytes T de la couronne du granulome tuberculeux. BCL2A1, CCL2 et CCL20 sont exprimés par les cellules myéloïdes mono-et multi-nucléées. Ensuite, nous avons caractérisé le phénotype, les fonctions immunitaires et l'activité microbicide des DC traitées par l'IL-17A. Nous avons trouvé qu’elles co-expriment des marqueurs de DC et de macrophages, conservent les fonctions classiques des DC, synthétisent un profil spécifique d’enzymes destructrices et exercent une microbicidie variable suivant les souches de Mycobactéries. Nous avons nommé GMIC (Giant Myeloid Inflammatory Cell), ces cellules géantes induites par l'IL-17A. Nous proposons qu'elles constituent un nouvel effecteur myéloïde qui contrôle les mycobactéries. Ainsi, l'IL-17A participerait au maintien du cœur myéloïde du granulome tuberculeux en favorisant la formation des cellules géantes possédant des fonctions destructrices et microbicides. Les mécanismes moléculaires que nous avons documentés devraient permettre le développement de nouvelles stratégies thérapeutiques et vaccinales contre la tuberculose

Les cellules géantes formées en présence de l interleukine-17Adans les granulomes de tuberculose (mécanismes de formation, de survie et fonctions)

Dans la tuberculose, Mycobacterium tuberculosis forme des granulomes dans les poumons avec, au centre, des cellules myéloïdes mono et multi-nucléées et autour, des lymphocytes. Nous avons étudié la biologie des cellules géantes dans ces granulomes tuberculeux: formation, mécanismes de survie et fonctions. Notre groupe a publié que l IL-17A déclenche la fusion des cellules dendritiques (DC). Notre travail démontre que cette cytokine induit BCL2A1/BFL1, qui régule la survie des DC et les chémokines CCL2 et CCL20 qui dirigent le regroupement nécessaire à leur fusion. In situ, l'IL-17A est exprimée par les lymphocytes T de la couronne du granulome tuberculeux. BCL2A1, CCL2 et CCL20 sont exprimés par les cellules myéloïdes mono-et multi-nucléées. Ensuite, nous avons caractérisé le phénotype, les fonctions immunitaires et l'activité microbicide des DC traitées par l'IL-17A. Nous avons trouvé qu elles co-expriment des marqueurs de DC et de macrophages, conservent les fonctions classiques des DC, synthétisent un profil spécifique d enzymes destructrices et exercent une microbicidie variable suivant les souches de Mycobactéries. Nous avons nommé GMIC (Giant Myeloid Inflammatory Cell), ces cellules géantes induites par l'IL-17A. Nous proposons qu'elles constituent un nouvel effecteur myéloïde qui contrôle les mycobactéries. Ainsi, l'IL-17A participerait au maintien du cœur myéloïde du granulome tuberculeux en favorisant la formation des cellules géantes possédant des fonctions destructrices et microbicides. Les mécanismes moléculaires que nous avons documentés devraient permettre le développement de nouvelles stratégies thérapeutiques et vaccinales contre la tuberculose.Tuberculosis, caused by Mycobacterium tuberculosis infection, results in the development of granulomas in affected tissues. These structures are formed by a myeloid cell core including multinucleated giant cells and surrounded by T lymphocytes. We studied mechanisms of survival, formation and functions of giant cells in Mycobacterium granulomas. Previously, our group showed that the cytokine IL-17A induces the fusion of dendritic cells (DC). Here, we identified molecules induced by the IL-17A genetic program in myeloid cells: BFL1 regulated DC survival, while the chemokines CCL2 and CCL20 directed clustering required for DC fusion. In situ, in human TB granulomas, we found that IL-17A was expressed by T lymphocytes while BFL1, CCL2 and CCL20 were expressed by the mono- and multi-nucleated myeloid cells. Then we characterized phenotype, immune functions and microbicidal activity of IL-17A-treated DC and their derived giant cells. They expressed a mixed DC-macrophage phenotype, retained classical DC functions, synthesized several destructive enzymes and had increased and differential microbicidal activities against Mycobacterium species. We named GMIC (giant myeloid inflammatory cells) these IL-17A-dependent giant cells, and propose that they constitute a new inflammatory myeloid effector with potent microbicidal activities. Altogether, our results show that IL-17A may participate in the maintenance of the myeloid core of human tuberculosis granuloma by promoting the formation of GMIC with potent destructive and microbicidal functions. The molecular mechanisms we have documented should help the development of new tuberculosis therapeutic and vaccination strategies.LYON-ENS Sciences (693872304) / SudocSudocFranceF

Impact of wars and population displacement on TB development, spreading, and resistance.

<p>Impact of wars and population displacement on TB development, spreading, and resistance.</p

Targeting BCL2 Family in Human Myeloid Dendritic Cells: A Challenge to Cure Diseases with Chronic Inflammations Associated with Bone Loss

Rheumatoid arthritis (RA) and Langerhans cell histiocytosis (LCH) are common and rare diseases, respectively. They associate myeloid cell recruitment and survival in inflammatory conditions with tissue destruction and bone resorption. Manipulating dendritic cell (DC), and, especially, regulating their half-life and fusion, is a challenge. Indeed, these myeloid cells display pathogenic roles in both diseases and may be an important source of precursors for differentiation of osteoclasts, the bone-resorbing multinucleated giant cells. We have recently documented that the proinflammatory cytokine IL-17A regulates long-term survival of DC by inducing BCL2A1 expression, in addition to the constitutive MCL1 expression. We summarize bibliography of the BCL2 family members and their therapeutic targeting, with a special emphasis on MCL1 and BCL2A1, discussing their potential impact on RA and LCH. Our recent knowledge in the survival pathway, which is activated to perform DC fusion in the presence of IL-17A, suggests that targeting MCL1 and BCL2A1 in infiltrating DC may affect the clinical outcomes in RA and LCH. The development of new therapies, interfering with MCL1 and BCL2A1 expression, to target long-term surviving inflammatory DC should be translated into preclinical studies with the aim to increase the well-being of patients with RA and LCH

Targeting BCL2 Family in Human Myeloid Dendritic Cells: A Challenge to Cure Diseases with Chronic Inflammations Associated with Bone Loss

Rheumatoid arthritis (RA) and Langerhans cell histiocytosis (LCH) are common and rare diseases, respectively. They associate myeloid cell recruitment and survival in inflammatory conditions with tissue destruction and bone resorption. Manipulating dendritic cell (DC), and, especially, regulating their half-life and fusion, is a challenge. Indeed, these myeloid cells display pathogenic roles in both diseases and may be an important source of precursors for differentiation of osteoclasts, the bone-resorbing multinucleated giant cells. We have recently documented that the proinflammatory cytokine IL-17A regulates long-term survival of DC by inducing BCL2A1 expression, in addition to the constitutive MCL1 expression. We summarize bibliography of the BCL2 family members and their therapeutic targeting, with a special emphasis on MCL1 and BCL2A1, discussing their potential impact on RA and LCH. Our recent knowledge in the survival pathway, which is activated to perform DC fusion in the presence of IL-17A, suggests that targeting MCL1 and BCL2A1 in infiltrating DC may affect the clinical outcomes in RA and LCH. The development of new therapies, interfering with MCL1 and BCL2A1 expression, to target long-term surviving inflammatory DC should be translated into preclinical studies with the aim to increase the well-being of patients with RA and LCH

Prevalence of anti-hepatitis E virus IgG antibodies in sera from hemodialysis patients in Tripoli, Lebanon.

Hepatitis E virus (HEV) is an important global public health concern. Several studies reported a higher HEV prevalence in patients undergoing regular hemodialysis (HD). In Lebanon, the epidemiology of HEV among HD patients has never been investigated previously. In this study, we examine the seroprevalence of HEV infection among 171 HD patients recruited from three hospital dialysis units in Tripoli, North Lebanon. Prevalence of anti-HEV IgG antibodies was evaluated in participant's sera using a commercial enzyme-linked immunosorbent assay (ELISA). The association of socio-demographic and clinical parameters with HEV infection in patients was also evaluated. Overall, 96 women and 75 men were enrolled in this study. Anti-HEV IgG antibodies were found positive in 37/171 HD patients showing a positivity rate of 21.63%. Among all examined variables, only the age of patients was significantly associated with seropositivity (P = 0.001). This first epidemiological study reveals a high seroprevalence of HEV infection among Lebanese HD patients. However, further evaluations that enroll larger samples and include control groups are required to identify exact causative factors of the important seropositivity rate in this population

Antimicrobial resistance in the protracted Syrian conflict : Halting a war in the war

The Syrian conflict has damaged key infrastructure and indirectly affected almost all parts of the Middle East and Europe, with no end in sight. Exhausting conditions created by the Syrian crisis and related massive displacement promote the emergence of numerous public health problems that fuel antimicrobial resistance (AMR) development. Here, we explore the current situation of the Syrian displaced population, and AMR inside Syria and among refugees in host countries. We then suggest a roadmap of selected key interventions and strategies to address the threat of AMR in the context of the Syrian crisis. These recommendations are intended to urge health policy-makers in governments and international health organizations to optimize and push for implementing an effective policy taking into consideration the current obstacles

Trends in the epidemiology of dermatophytosis in the Middle East and North Africa region

International audienc